Department of Internal Medicine, University of Kansas Cancer Center, Fairway, Kansas, USA.
Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Clin Transl Sci. 2024 Jun;17(6):e13854. doi: 10.1111/cts.13854.
SAR439459 (SAR'459), a "second-generation" human anti-transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459 ± cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3 weeks (Q2W, Q3W) alone (Part 1A) or with 3 mg/kg cemiplimab Q2W or 350 mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5 mg/kg SAR'459. In Part 2B (dose expansion), 22.5 mg/kg SAR'459 and 350 mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty-eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5 mg/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness-of-fit plots and adequately described the observed data by a two-compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment-emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.
SAR439459(SAR'459)是一种“第二代”人源抗转化生长因子-β(TGFβ)单克隆抗体,可增强免疫检查点抑制剂的活性。在这项 I/ Ib 期研究中,我们评估了 SAR'459±cemiplimab(静脉注射)在晚期实体瘤患者中的安全性、药代动力学(PK)、药效学和抗肿瘤活性。单独递增剂量的 SAR'459 每 2 或 3 周(Q2W,Q3W)给药(部分 1A)或与 3mg/kg cemiplimab Q2W 或 350mg Q3W 给药(部分 1B)。在部分 2A(剂量扩展)中,黑素瘤患者以 1:1 的比例随机接受 22.5 或 7.5mg/kg SAR'459 治疗。在部分 2B(剂量扩展)中,22.5mg/kg SAR'459 和 350mg cemiplimab Q3W 联合给药。主要终点为最大耐受剂量(MTD)或最大给药剂量(MAD;部分 1)、初步抗肿瘤活性(部分 2B)和最佳单药剂量(部分 2A)。部分 1A 和 1B 分别有 28 例和 24 例患者接受治疗;未达到 MTD,MAD 分别为 15(Q2W)和 22.5mg/kg(Q3W)单独和联合用药。部分 2A 和 2B 分别有 14 例和 95 例患者接受治疗,其中包括 14 例肝细胞癌(HCC)患者。群体 PK 模型产生了令人满意的拟合良好的图,并且通过具有线性消除的两室 PK 模型充分描述了观察到的数据。在第 1 部分和第 2A 部分未观察到客观反应。在第 2B 部分,肿瘤类型和 HCC 队列的客观缓解率分别为 8.4%和 7.1%。最常见的治疗相关不良事件是出血事件(43.5%)、角化棘皮瘤(6.8%)和皮肤肿瘤(6.2%)。尽管采取了缓解措施,但 21.4%的 HCC 患者仍发生致命性出血。SAR'459 单药治疗和联合 cemiplimab 治疗在剂量递增中对少数患者相对安全且耐受。然而,由于 SAR'459 的疗效和出血风险不明确,特别是在 HCC 患者中,该研究已被终止。